$219 Million

Praxis Precision Medicines

Initial Public Offering

Lead Left Bookrunner, October 2020

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. The Company’s portfolio includes five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes. The Company’s lead clinical program, PRAX-114, is an extrasynaptic-preferring GABAA receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). The Company’s second clinical program, PRAX-944, is a potential differentiated selective small molecule inhibitor of T-type calcium channels for the treatment of Essential Tremor (ET).

More Like This

Nov 2020
$240 Million

Initial Public Offering

Bookrunner

View Details
Oct 2020
$135 Million

Initial Public Offering

Bookrunner

View Details
Oct 2020
$104 Million

Initial Public Offering

Lead Left Bookrunner

View Details